Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP501123.RAfOoky7cfhkGLdupBPn0V3Jbno2ImganTFPrLIS1S2Xo130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP501123.RAfOoky7cfhkGLdupBPn0V3Jbno2ImganTFPrLIS1S2Xo130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP501123.RAfOoky7cfhkGLdupBPn0V3Jbno2ImganTFPrLIS1S2Xo130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP501123.RAfOoky7cfhkGLdupBPn0V3Jbno2ImganTFPrLIS1S2Xo130_provenance.
- NP501123.RAfOoky7cfhkGLdupBPn0V3Jbno2ImganTFPrLIS1S2Xo130_assertion description "[To identify the promising alternative approach, we investigated the therapeutic potential of targeting the interleukin (IL)-8/CXCR2 pathway in colon cancer treatment using both loss-of-function (CXCR2 knockout) and gain-of-function (IL-8 overexpression) mouse models, as the IL-8/CXCR2 pathway has been shown to be activated in intestinal tumors of both human and experimental animals.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP501123.RAfOoky7cfhkGLdupBPn0V3Jbno2ImganTFPrLIS1S2Xo130_provenance.
- NP501123.RAfOoky7cfhkGLdupBPn0V3Jbno2ImganTFPrLIS1S2Xo130_assertion evidence source_evidence_literature NP501123.RAfOoky7cfhkGLdupBPn0V3Jbno2ImganTFPrLIS1S2Xo130_provenance.
- NP501123.RAfOoky7cfhkGLdupBPn0V3Jbno2ImganTFPrLIS1S2Xo130_assertion SIO_000772 24338666 NP501123.RAfOoky7cfhkGLdupBPn0V3Jbno2ImganTFPrLIS1S2Xo130_provenance.
- NP501123.RAfOoky7cfhkGLdupBPn0V3Jbno2ImganTFPrLIS1S2Xo130_assertion wasDerivedFrom befree-20150227 NP501123.RAfOoky7cfhkGLdupBPn0V3Jbno2ImganTFPrLIS1S2Xo130_provenance.
- NP501123.RAfOoky7cfhkGLdupBPn0V3Jbno2ImganTFPrLIS1S2Xo130_assertion wasGeneratedBy ECO_0000203 NP501123.RAfOoky7cfhkGLdupBPn0V3Jbno2ImganTFPrLIS1S2Xo130_provenance.
- befree-20150227 importedOn "2015-02-27" NP501123.RAfOoky7cfhkGLdupBPn0V3Jbno2ImganTFPrLIS1S2Xo130_provenance.